Secondary key points included a change from baseline on the ADAS-Cog13 Score, Alzheimer’s Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL) Score, CDR-SB Score, MMSE Score, brain aggregated tau deposition measured by PET scan, brain volume measured by MRI, and Columbia Suicide Severity Rating Scale (C-SSRS); also, identifying the number of patients that developed treatment-emergent anti-drug antibodies (TE-ADA) was a secondary measured outcome. Here, ADA is linked to early-onset autosomal dominant Alzheimer disease.